Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report
Clinical Case Reports · 2026-04 · 14 (4)
DOI: 10.1002/ccr3.72234 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 30.03.2026. Verfasst von Reyad Dada und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Orphan Biovitrum.
Abstract (Originalsprache)
Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose modification.
Förderung
- Swedish Orphan Biovitrum
Zitieren
APA
Dada, R., & Ibrahim, R. B. (2026). Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report. Clinical Case Reports, 14(4). https://doi.org/10.1002/ccr3.72234
Vancouver
Dada R, Ibrahim RB. Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report. Clinical Case Reports. 2026;14(4). doi:10.1002/ccr3.72234
BibTeX
@article{Dada2026,
author = {Dada, Reyad and Ibrahim, Refaei Belal},
title = {Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report},
journal = {Clinical Case Reports},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/ccr3.72234}
}
EUVIMED